Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease.
Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease.
复制标题
DOI：
10.1155/2005/806573
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
Lee KH
中科院分区：
文献类型：
--
作者：
Finehout EJ;Franck Z;Lee KH
已经表明补体系统的激活涉及几种神经退行性疾病的发病机制，包括阿尔茨海默病（AD）、帕金森病（PD）和多发性硬化症（MS）。在此，比较了正常受试者与诊断为AD、PD、MS和神经梅毒的患者之间补体蛋白C3 B、C4 B、因子B和因子H的CSF表达水平。最初使用二维凝胶电泳分离CSF蛋白，这允许比较一些个体补体同种型。与正常受试者相比，患有AD、PD和MS的患者都显示出一种以上的补体同种型，CSF表达水平有显著变化（p < 0.05）。发现PD患者具有最大数量的显著改变的同种型，所有这些同种型在PD CSF中均显示出表达水平降低。检查的补体亚型能够区分一些，但不是所有的疾病研究。数据表明，当研究蛋白质作为可能的生物标志物时，除了更常见的总蛋白质表达水平外，还可以比较单个蛋白质亚型表达水平。
It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor B, and factor H were compared between normal subjects and patients diagnosed with AD, PD, MS, and neurosyphilis. The CSF proteins were initially separated using two-dimensional gel electrophoresis, which allowed the comparison of some of the individual complement isoforms. Patients with AD, PD, and MS all showed more than one complement isoform with a significant change (p < 0.05) in CSF expression level compared to normal subjects. PD patients were found to have the greatest number of significantly changed isoforms, all showing a decreased expression level in PD CSF. The complement isoforms examined were able to distinguish between some, but not all, of the diseases studied. The data suggest that when investigating a protein as a possible biomarker, it may be useful to compare individual protein isoform expression levels in addition to the more commonly measured total protein expression level.
登录
查看更多内容
影响因子：
2.9
作者：
Finehout, EJ;Lee, KH
通讯作者：
Lee, KH
影响因子：
2.9
作者：
LUMSDEN, CE
通讯作者：
LUMSDEN, CE
影响因子：
4.2
作者：
SMYTH, MD;CRIBBS, DH;SHANKLE, WR
通讯作者：
SHANKLE, WR
影响因子：
6
作者：
Yasojima, K;Schwab, C;McGeer, PL
通讯作者：
McGeer, PL
DOI：
10.1016/s0162-3109(99)00015-6
发表时间：
1999-05-01
期刊：
IMMUNOPHARMACOLOGY
影响因子：
--
作者：
Zipfel, PF;Jokiranta, TS;Meri, S
通讯作者：
Meri, S